Medigard selects site for trials

By Dylan Bushell-Embling
Thursday, 10 July, 2008

Medical device company Medigard [ASX; MGZ] will conduct clinical trials of its proprietary safety blood collection devices at Griffith University's Gold Coast campus.

The trials will be held at the university's Genomics Research Centre. 500 of the devices have been delivered to the centre for simulated clinical trials.

The trials are part of the company's FDA 510(k) application, a fast-tracking process for important, innovative or advanced medical devices.

Related News

Organoid platform enables closer study of bat-borne viruses

Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...

Global study finds 250 genes linked to OCD

Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...

TGA approves therapy for paediatric growth hormone deficiency

The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd